On September 17, 2026, the U.S. Food and Drug Administration approved Fayuvi (rebisufligene etisparvovec-hopf), the first FDA-approved gene therapy for certain children with Sanfilippo syndrome type A. The decision matters because this inherited disorder progressively damages the brain and nervous system, while care has historically focused on symptoms and support. This article explains what was approved, how the therapy is designed to work, what evidence supported the decision, and what families should ask their specialist team.
Important safety note: This approval does not make the therapy appropriate for every child with Sanfilippo syndrome. Eligibility, testing, infusion planning, immune management, and long-term follow-up require an experienced metabolic and gene-therapy team.
What the FDA approved
The approved product is a one-time intravenous gene therapy. According to the FDA approval letter, its indication is the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA), also called Sanfilippo syndrome type A, in pediatric patients who still have preserved neurodevelopmental function. That qualification is important: the formal indication is narrower and more clinically specific than simply saying the product is for every child with MPS IIIA.
| Approval detail | What it means | Why it matters |
|---|---|---|
| Condition | MPS IIIA, or Sanfilippo syndrome type A | The approval does not cover the B, C, or D subtypes |
| Population | Pediatric patients with preserved neurodevelopmental function | A specialist must assess whether a child fits the labeled indication |
| Administration | One intravenous infusion in a qualified healthcare setting | Preparation and monitoring extend well beyond the infusion day |
| Therapy type | AAV9-based gene therapy delivering a working SGSH gene | The goal is to address the missing or deficient enzyme at its source |
The FDA also granted the therapy Orphan Drug, Fast Track, and Breakthrough Therapy designations during development. Those designations describe regulatory pathways and the seriousness of the unmet need; they do not remove the need to weigh benefits, uncertainties, and risks for each eligible patient.
Why Sanfilippo syndrome type A is so serious
Sanfilippo syndrome is a lysosomal storage disorder. In type A, disease-causing variants in both copies of the SGSH gene lead to too little functional sulfamidase, also called N-sulfoglucosamine sulfohydrolase. Without enough of this enzyme, cells cannot properly break down heparan sulfate. The material accumulates, and the nervous system is especially affected.
Children may initially develop in ways that do not immediately reveal the condition. Language delay, behavioral changes, sleep problems, hearing loss, and later loss of previously acquired abilities can become prominent. The timing and speed of progression vary. Physical concerns can also involve the airway, hearing, joints, heart, vision, feeding, and recurrent respiratory or ear infections.
The central meaning of this approval is not that every problem caused by MPS IIIA has been solved, but that clinicians now have an FDA-approved option intended to alter the disease process for a defined group of children.
How diagnosis is confirmed
Symptoms alone cannot confirm MPS IIIA. Specialist evaluation may include biochemical testing for enzyme activity and molecular testing that identifies pathogenic variants in SGSH. Urine glycosaminoglycan testing can support an evaluation, but a normal urine result does not reliably exclude MPS III. Because several developmental and behavioral conditions can look similar early on, interpretation belongs with clinicians experienced in metabolic and genetic disease.
How the gene therapy is designed to work
Fayuvi uses a modified, non-infectious adeno-associated virus serotype 9, or AAV9, as a delivery vehicle. The vector carries a working copy of the SGSH gene into cells. The aim is for those cells to produce sulfamidase so that heparan sulfate can be broken down more effectively in lysosomes.
This approach is different from repeatedly supplying an enzyme or treating one symptom at a time. It is intended as a single administration, but “one time” should not be confused with “one visit.” Evaluation before infusion, corticosteroid use, laboratory surveillance, management of adverse effects, and long-term monitoring are part of the treatment pathway.
| Stage | What happens | Key question for families |
|---|---|---|
| Before treatment | Diagnosis, eligibility, organ function, immune status, and baseline development are reviewed | Which findings determine whether my child fits the indication? |
| Infusion period | The therapy is given intravenously in a prepared clinical setting | How will the team prevent and manage infusion-related problems? |
| Early follow-up | Blood counts, liver tests, symptoms, and other safety measures are monitored | Which changes should prompt an urgent call to the treatment center? |
| Long-term follow-up | Development, function, safety, and possible delayed risks are tracked | What visits and tests will be required over the coming years? |
What evidence supported approval
The FDA described an open-label, single-arm, multicenter study in children with MPS IIIA. In an open-label study, families and investigators know that treatment is being given. In a single-arm study, there is no concurrent randomized control group. Researchers therefore compared treated children with an untreated historical control cohort representing the expected natural course of the disease.
The main clinical comparison involved changes in cognitive scores among children ages 2 to 5. The FDA reported that treated patients maintained or improved cognitive function compared with the historical cohort, whose expected course involved plateau and decline. This was considered a meaningful difference during a critical period of development.
Why natural-history data matter
Rare, progressive diseases can make conventional large trials difficult. Carefully collected natural-history data help researchers understand what usually happens without a disease-modifying therapy. A published review of 46 children with MPS IIIA documented speech and language delay, hearing loss, sleep difficulty, behavioral changes, and rapid cognitive decline in early childhood, illustrating why age, baseline function, and disease trajectory are central to interpreting treatment outcomes.
What the study design cannot answer alone
Historical controls are useful, but they are not identical to a randomized group enrolled and assessed at the same time. Differences in supportive care, testing methods, patient selection, or available records can affect comparisons. An open-label design can also introduce bias. The approval therefore represents a positive regulatory judgment based on the available total evidence, not a guarantee that every treated child will have the same response.
| Evidence point | What is encouraging | What remains uncertain |
|---|---|---|
| Cognitive outcome | Treated children maintained or improved function relative to historical controls | The size and durability of benefit may differ among children |
| Single administration | One infusion may provide sustained gene delivery | Long-term persistence and late effects require continued observation |
| Mechanism | The therapy supplies a working copy of the deficient gene | Gene delivery may not reverse injury that has already occurred |
| Rare-disease trial | Multicenter data addressed an urgent unmet need | A nonrandomized historical comparison carries limitations |
Known risks and safety monitoring
The FDA reported adverse reactions occurring in more than 5% of treated patients, including increased aspartate aminotransferase, nausea and vomiting, fever, reduced appetite, decreased white blood cell and platelet counts, and increased amylase. The agency also highlighted thrombotic microangiopathy, a potentially serious condition involving small blood vessels and blood components, as an important warning.
As with other AAV-based gene therapies, the FDA noted a potential long-term risk that inserted genetic material could integrate into the genome and contribute to tumor development. “Potential” is the right word: it signals a risk requiring surveillance, not a prediction that a treated child will develop cancer.
Patients receive corticosteroid treatment beginning before the infusion and continuing afterward, according to the FDA announcement. Steroid plans and any other medicines must be directed by the treatment team. Families should not start, stop, or adjust corticosteroids or other medicines based on general online information.
- Ask which blood, liver, kidney, pancreatic, and urine tests are required.
- Request a written list of symptoms that require same-day contact or urgent assessment.
- Confirm who is available after hours and which hospital should evaluate a possible complication.
- Discuss infection precautions and vaccination timing with the specialist team.
- Keep the long-term follow-up schedule even when the child appears well.
What this approval does not mean
The approval is a major milestone, but several boundaries deserve plain language. It does not mean the therapy reverses all existing neurologic injury. It does not establish that every child will respond, and it does not replace multidisciplinary care. Nor does it apply automatically to every form of Sanfilippo syndrome: types B, C, and D involve different genes and enzymes.
Supportive services remain important. Depending on a child’s needs, care may involve metabolic genetics, neurology, developmental pediatrics, rehabilitation, speech and communication support, audiology, sleep care, cardiology, pulmonology, nutrition, behavioral health, social work, and palliative care. Disease-modifying treatment and supportive care are not competing approaches; they address different parts of a complex condition.
Questions families can take to the care team
A specialist conversation is more productive when it separates eligibility, expected benefit, immediate safety, and long-term uncertainty. Families may wish to bring records of genetic testing, enzyme studies, developmental evaluations, current medicines, prior procedures, allergies, infections, and other medical conditions.
- Does my child’s diagnosis and current neurodevelopmental function match the FDA-approved indication?
- What baseline tests are needed, and what findings could delay or prevent treatment?
- What outcome is realistic for my child, and which changes are unlikely to be reversed?
- How were children similar to mine represented in the evidence reviewed by the FDA?
- What are the most important short-term and long-term risks?
- How will corticosteroids and other supportive medicines be managed?
- Where will the infusion occur, and what expertise does the center have with pediatric gene therapy?
- What developmental, laboratory, and safety follow-up is required after treatment?
How to interpret future updates
Evidence will continue to develop after approval. Useful updates will report how long developmental benefits persist, whether outcomes differ by age or baseline function, how safety findings evolve, and what happens in broader real-world use. Reports should be interpreted in light of the number of patients, follow-up duration, comparison group, and whether results have undergone regulatory or peer review.
Families should be cautious with testimonials presented as proof. Individual stories can communicate lived experience, but they cannot establish average benefit, identify uncommon harms, or predict another child’s outcome. Regulatory documents, peer-reviewed studies, and the child’s specialist team provide a firmer basis for decisions.
Bottom line
The FDA approval of Fayuvi is the first for a gene therapy aimed at the neurologic manifestations of Sanfilippo syndrome type A in pediatric patients with preserved neurodevelopmental function. The therapy delivers a working SGSH gene through an AAV9 vector and is given as a one-time intravenous infusion. Evidence reviewed by the FDA showed a favorable cognitive difference compared with an untreated historical cohort, while important short-term and potential long-term risks require specialized monitoring.
For families, the next step is not self-screening or changing care independently. It is a detailed discussion with an experienced metabolic genetics and gene-therapy center about the precise indication, likely benefit, treatment burden, uncertainties, and lifelong follow-up. General health information cannot replace individualized medical advice.
Sources
- U.S. Food and Drug Administration: FDA approves first gene therapy for pediatric patients with Sanfilippo syndrome type A
- U.S. Food and Drug Administration: Fayuvi biologics license approval letter
- NIH Genetic and Rare Diseases Information Center: MPS IIIA disease overview
- NCBI Bookshelf GeneReviews: Mucopolysaccharidosis type III
- NIH Genetic Testing Registry: Mucopolysaccharidosis type IIIA
- PubMed: Natural history of Sanfilippo syndrome type A
